Please ensure Javascript is enabled for purposes of website accessibility

Repligen Signals Gene Therapy Strength With 2019 Earnings Report

By Maxx Chatsko - Updated Feb 21, 2020 at 5:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Guidance for 2020 appears to have spooked investors, but the bioprocess leader is on a solid long-term trajectory.

When is achieving year-over-year growth of 39% for both revenue and operating income not enough? When guidance for the next year disappoints, apparently.

Repligen (RGEN 2.72%) delivered a solid fourth-quarter and full-year 2019 earnings report yesterday. A combination of new product launches, continued contributions from past acquisitions, and growing demand for bioprocess products drove significant increases in nearly every financial metric. The company also reported that gene therapy customers were responsible for 15% of total revenue in 2019 and remain one of the best sources of growth.

Despite the progress, investors appear to have been disappointed by full-year 2020 guidance for revenue growth of 14% to 18%. That's much lower than the most recent annual period. Considering Repligen is one of the more closely watched growth stocks on the market, it's not surprising that shares took a tumble on the relatively weak guidance. But it might be just a matter of perspective.

Wooden blocks reading 2019, with an 8 in the background.

Image source: Getty Images.

By the numbers

Repligen develops bioprocessing equipment. It sells the products required to manufacture biologic drugs such as monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and cellular therapies. For instance, it sells products needed to grow cell cultures, equipment required to separate and filter the components of gene therapy vector manufacturing, and the products that make it possible to efficiently purify therapeutic proteins.

It might be an overlooked niche, but it's a lucrative one. Repligen has leaned on acquisitions to bolster its product portfolio and in-house expertise to develop new products. Acquisitions were responsible for roughly 40% of all revenue generated from 2014 to 2019. Meanwhile, the company launched 12 new products from research and development efforts during that span. 

That blueprint drove significant growth in 2019 and delivered the most profitable year yet for Repligen. 




Change (YOY)


$270.2 million

$194.0 million


Gross profit

$151.1 million

$107.5 million


Gross margin



50 basis points

Operating income

$36.0 million

$26.0 million


Net income

$21.4 million

$16.6 million


Adjusted earnings per share (EPS) 




Data source: Press release. YOY = year over year.

Coincidentally, the company's product portfolio is well suited to serve the fledgling gene therapy and cell culture markets. The product-market fit may not have been the primary factor supporting every acquisition made in recent years, but each has contributed to the opportunity.

Gene therapy customers were responsible for an estimated 15% of total revenue in 2019. By comparison, gene therapy applications were responsible for an estimated 4% of sales in 2017. That suggests revenue from gene therapy customers has grown from less than $6 million in 2017 to $40 million in 2019.  

If gene therapy is a strength, why is 2020 guidance weak? 

Investors might be having a difficult time squaring the strength in gene therapy markets with relatively weak full-year 2020 guidance. After all, annual revenue jumped 39% in 2019, but Repligen expects to grow at half that rate in a best-case scenario for 2020. 


Full-Year 2020, Guidance

Full-Year 2019, Actual

Change (YOY)


$309 million to $319 million

$270 million

14% to 18%

Gross margin

55% to 56%


(90 basis points) to 10 basis points

Operating income

$50 million to $54 million

$36 million

39% to 50%

Adjusted EPS

$1.07 to $1.12


0% to 5%

Data source: Press release. YOY = year over year.

What's going on? CEO Tony Hunt explained on the fourth-quarter 2019 earnings conference call that the weak year-over-year comparisons for 2020 have more to do with a stronger-than-expected performance last year than any real weakness in the year ahead. The OPUS business (chromatography columns used to purify cell culture products) had a big year, while the fast rise of gene therapy has surprised everyone:

Our OPUS business came off a massive year last year, up over 50%. And our filtration product line also had a really, really big year. ...

I think the other factor last year is that no one really in the industry predicted how fast the gene therapy market was going to grow. And I think we all kind of missed that a little bit. And so that's kind of the explanation for last year.

It's also worth pointing out that the oldest part of the business is providing a non-negligible headwind. Repligen is a leading provider of protein A ligands, the secret sauce that allows chromatography columns and other purification products to work. It manufactures proteins for its own OPUS columns and also sells them to others in the industry as an original equipment manufacturer. 

While the company has reduced its dependence on the protein segment from 72% of total revenue in 2014 to just 24% in 2019, it's still a sizable part of the overall business and can weigh on results when headwinds emerge. 

Don't be spooked by "weak" 2020 guidance

On the one hand, Repligen's stock trades at a healthy premium. Any sign of real or perceived weakness is bound to have a negative effect on the share price. 

On the other hand, investors with a long-term mindset should see no real cause for concern. There are slightly over 100 monoclonal antibody products on the market today, but over 550 in clinical trials. Similarly, there are eight gene therapy and cell therapy products on the market today, but over 1,000 in clinical trials. That provides a healthy pipeline of growth for Repligen, which can monetize the opportunity from clinical trials all the way through commercial-scale production. 

Additionally, Repligen has set the goal of achieving $500 million to $600 million in annual revenue by 2023. That means it expects to roughly double revenue in the next four years. Considering it began the year with $528 million in cash and has a history of making growth-focused investments and acquisitions, investors shouldn't be surprised if management makes an acquisition before the end of 2020. 

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool recommends Repligen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Repligen Corporation Stock Quote
Repligen Corporation
$252.97 (2.72%) $6.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.